Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Impax Labs upgrade details — to Buy at Deutsche Bank; tgt $11 (9.45 +0.35)Deutsche Bank upgrades IPXL to Buy from Hold and sets target price at $11 as they believe patient investors could be rewarded if business trends improve, or if strategic options (such as a sale) are pursued. Firm raised this possibility in a previous note, and a recent <em>Reuters</em> article (from 3/7/17) suggested that IPXL hired an investment bank to help it explore strategic options which could include an acquisition or sale of co. <strong>Firm likes the set up for the stock from here, and are moving to a Buy rating as tgt based on stand-alone assumptions (not without risks) supports material upside, while a potential M&A scenario based on historical acquisition multiples could support much higher prices.</strong></td> </tr></table>"